Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world observational study of Songling Xuemaikang Capsule for primary hypertension
ChiCTR-ONC-11001612Phase 4Recruiting
- Sponsor
- Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine
- Start
- Jun 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of songling xuemaikang in essential hypertension, sponsored by Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine. Primary endpoint: Changes in diastolic pressure. Started Jun 2011; status: recruiting.
02
Drugs
songling xuemaikang
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ChiCTR-ONC-11001612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-11001612.